Shield Therapeutics (GB:STX) has released an update.
Shield Therapeutics plc, a commercial stage pharmaceutical company, is set to announce its interim results for the first half of 2024 on September 4th. The company, known for its innovative oral iron treatment Accrufer®/Feraccru®, addresses iron deficiency in patients globally. An investor presentation by the Interim CEO and CFO will be hosted online, open to all interested parties.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.
